Overview
Status
Active
Registry date
2019-05-24
Share capital
100,000.00 PLN
Registered address
ul. Jana Żabińskiego 3/14, 02-793 Warszawa, Poland
Email
Financials
Only balance sheet data (assets and liabilities) is available. The income statement (P&L) is not available in the source filing for this period.
Revenue history (in k)
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 91 days for 2023).
- 202523/06/2026
- 202414/07/2025
- 202314/10/2024
- 202218/08/2023
- 202112/10/2022
- 202013/10/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Industry
Public procurement
No recorded participation in tenders.
Upward Pharma has been a party to 1 case before the National Appeal Chamber (since 2019).
| Date | Subject of dispute | Outcome | Other party | |
|---|---|---|---|---|
| Sep 13, 2019 | Tender evaluation criteria | Dismissed | Zakład Zamówień Publicznych przy Ministrze Zdrowia |
Authorized Representatives
Michał Ambroziak – Liquidator
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Michał Ambroziakage 44 | 1,500 | $20,259.32 | 75% |
Magdalena Liliana Pachowskaage 40 | 500 | $6,753.11 | 25% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Was a VAT taxpayer from 2019-06-08 to 2024-06-30.
Reason for removal: Art. 96 ust. 6-8
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Mar 13, 2023 | Liquidation opened |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
Change history
| Date | Event | |
|---|---|---|
| 2023-03-28 | Name change (Upward Pharma → Upward Pharma Spółka Z Ograniczoną Odpowiedzialnością W Likwidacji) | |
| 2023-03-01 | Liquidation opened | |
| 2022-08-10 | Address change (Ul. Żurawia 32/34/49, 00-515, Warszawa → Ul. Jana Żabińskiego 3/14, 02-793, Warszawa) | |
| 2020-10-20 | Address change (Ul. Kłobucka 23a, 02-699, Warszawa → Ul. Żurawia 32/34/49, 00-515, Warszawa) | |
| 2019-05-24 | Entered in the register |
FAQ
The company was registered in the Polish National Court Register (KRS) on May 24, 2019.
The headquarters is located at: ul. Jana Żabińskiego 3, 02-793 Warszawa.
The share capital of the company is PLN 100,000 (approx. $27,012).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $57,612 in 2024, which is an increase of 4531.5% compared to 2023.
Yes, the company recorded a net profit of $57,469 in 2024.
The largest operating cost category falls under other operating costs. This category amounted to $142 in 2024, representing 100% of all operating expenses.
Last updated: 2026-06-23